Advertisement
JNJ vs PFE
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Johnson & Johnson (JNJ) continues to benefit from a diversified healthcare model spanning pharmaceuticals, medical devices, and consumer health, providing resilience amid sector-specific headwinds.
- Pfizer (PFE) has faced post-pandemic revenue normalization, with declining COVID-19 product sales pressuring top-line growth, though cost-cutting measures and pipeline advancements are underway.
- JNJ's recent relative price stability contrasts with PFE's more volatile trajectory, reflecting differing market sentiment around each company's growth catalysts and risk profiles.
- Both companies maintain strong dividend track records, appealing to income-oriented investors, but their near-term growth narratives diverge considerably.
- Tickeron's AI-driven analysis evaluates trend consistency, volatility, and momentum to identify which stock currently exhibits more favorable characteristics under prevailing market conditions.
Introduction
Johnson & Johnson and Pfizer stand as two titans of the global pharmaceutical industry, each commanding significant market capitalizations and decades of operational history. While both operate within the healthcare sector, their business structures, growth trajectories, and market perceptions have diverged in notable ways. This comparison is particularly relevant for investors weighing defensive healthcare allocations, dividend-focused portfolios, or sector-specific exposure. Whether you are a long-term investor evaluating stability and income or a trader assessing momentum and relative strength, understanding how these two pharmaceutical giants stack up against each other in the current market environment offers valuable perspective on healthcare sector positioning.
JNJ Overview and Recent Performance
JNJ, Johnson & Johnson, is one of the world's largest and most diversified healthcare companies, operating across three core segments: Innovative Medicine (pharmaceuticals), MedTech (medical devices), and previously Consumer Health before its Kenvue spin-off. This diversified structure has historically provided JNJ with a degree of insulation against sector-specific downturns. In recent weeks, JNJ's stock has demonstrated relatively steady performance, supported by solid pharmaceutical sales in key therapeutic areas such as oncology and immunology, as well as recovering medical device volumes. The company's decision to complete the Kenvue separation has allowed management to sharpen focus on higher-growth pharmaceutical and MedTech segments. Broader market activity has reflected cautious optimism around JNJ's pipeline, including regulatory progress in multiple myeloma and other oncology treatments. While legal liabilities related to talc litigation remain an overhang, the company has pursued resolution strategies that have been met with mixed investor reactions. Overall, JNJ's recent stock behavior reflects a blend of defensive stability and measured growth expectations.
PFE Overview and Recent Performance
PFE, Pfizer Inc., is a global biopharmaceutical company with a broad portfolio spanning oncology, immunology, vaccines, rare diseases, and internal medicine. Pfizer experienced a dramatic revenue surge during the COVID-19 pandemic driven by its Comirnaty vaccine and Paxlovid antiviral treatment, but the subsequent normalization of demand has created significant headwinds. In recent months, PFE's stock has faced downward pressure as investors recalibrated expectations around post-pandemic revenue levels. The company has responded with an aggressive cost-realignment program aimed at reducing expenses by billions of dollars, alongside strategic acquisitions — most notably the Seagen acquisition, which bolsters Pfizer's oncology pipeline with antibody-drug conjugate (ADC) technology. Recent market sentiment has been mixed, with some investors viewing the stock as undervalued relative to its pipeline potential while others remain cautious about near-term earnings trajectory. The dividend remains a key attraction, though payout sustainability metrics are being closely watched amid revenue normalization.
Trending AI Robots
In today's fast-moving markets, individual investors are increasingly turning to AI-powered tools to help navigate complex trading decisions. Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots — selected from hundreds of available bots that collectively trade thousands of different tickers across diverse market conditions. These bots are designed with varying trading styles, from short-term swing trading to longer-term trend following, and each has distinct performance statistics, risk parameters, and stock universes. Only the bots demonstrating the strongest real-time alignment with current market dynamics earn placement in this section, helping users quickly identify strategies that are proving effective right now. Some featured bots have reported annualized returns ranging from the mid-teens to over 30%, depending on strategy and market exposure, with varying drawdown profiles. Discover which AI trading bots are currently trending and explore how data-driven strategies can complement your investment approach by visiting the Trending AI Robots page.
Head-to-Head Comparison
When comparing JNJ and PFE, several key dimensions stand out. From a business model perspective, JNJ's diversified structure across pharmaceuticals and medical devices provides a broader revenue base compared to Pfizer's more focused biopharmaceutical model. This diversification has historically translated into lower earnings volatility for JNJ, while Pfizer's narrower focus can amplify both upside and downside from pipeline successes or failures.
In terms of growth drivers, JNJ is leveraging its immunology and oncology franchises alongside MedTech innovation, with Darzalex, Stelara, and pipeline assets serving as key catalysts. Pfizer, meanwhile, is betting heavily on its Seagen acquisition to transform its oncology presence, while managing the transition away from pandemic-era revenue dependency.
Recent momentum has favored JNJ, which has exhibited comparatively stronger relative performance over recent months as investors gravitate toward its defensive characteristics and clearer near-term earnings visibility. PFE has faced a more challenging price environment, though some value-oriented investors view the depressed valuation as a potential opportunity.
Regarding risk factors, JNJ contends with ongoing talc-related litigation uncertainties and biosimilar competition for key products. PFE's risks center on faster-than-expected COVID product revenue erosion and integration execution risk tied to the Seagen acquisition. Both stocks face broader sector risks including drug pricing legislation and patent cliffs (the expiration of patents that protect revenue from branded drugs).
On market sentiment, JNJ is currently perceived as the more stable, "sleep-well-at-night" holding, while PFE is increasingly viewed as a turnaround story requiring patience and conviction.
Tickeron AI Verdict
Based on the observable factors assessed by Tickeron's AI analytical framework, Johnson & Johnson (JNJ) currently appears to demonstrate more favorable characteristics relative to Pfizer (PFE). The AI-driven evaluation considers JNJ's stronger trend consistency, lower relative volatility, and a more clearly defined near-term catalyst path. While Pfizer's valuation may appeal to contrarian investors and its oncology pipeline holds long-term promise, the prevailing momentum and stability metrics favor JNJ in the current environment. The diversified revenue streams and post-Kenvue strategic clarity provide JNJ with a steadier footing amid macroeconomic uncertainty. That said, market conditions are dynamic, and a shift in sentiment around Pfizer's pipeline progress or cost-realignment execution could alter this assessment. The AI's probabilistic approach suggests JNJ currently holds an edge, but both stocks warrant ongoing monitoring as new data emerges.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and PFE is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 4 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).
- JNJ’s FA Score: 4 green, 1 red.
- PFE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 5 TA indicator(s) are bullish while PFE’s TA Score has 4 bullish TA indicator(s).
- JNJ’s TA Score: 5 bullish, 4 bearish.
- PFE’s TA Score: 4 bullish, 5 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а +4.09% price change this week, while PFE (@Pharmaceuticals: Major) price change was -0.52% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.95%. For the same industry, the average monthly price growth was +1.76%, and the average quarterly price growth was +4.67%.
Reported Earning Dates
JNJ is expected to report earnings on Oct 20, 2026.
PFE is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.95% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| JNJ | PFE | JNJ / PFE | |
| Capitalization | 635B | 140B | 454% |
| EBITDA | 33.7B | 17.2B | 196% |
| Gain YTD | 28.690 | 3.810 | 753% |
| P/E Ratio | 30.56 | 18.73 | 163% |
| Revenue | 96.4B | 63.3B | 152% |
| Total Cash | 22.1B | N/A | - |
| Total Debt | 55B | 63.7B | 86% |
JNJ | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 39 | 12 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 100 | |
SMR RATING 1..100 | 36 | 77 | |
PRICE GROWTH RATING 1..100 | 11 | 57 | |
P/E GROWTH RATING 1..100 | 13 | 43 | |
SEASONALITY SCORE 1..100 | 75 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (5) in the Pharmaceuticals Major industry is in the same range as JNJ (15). This means that PFE’s stock grew similarly to JNJ’s over the last 12 months.
JNJ's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that JNJ’s stock grew significantly faster than PFE’s over the last 12 months.
JNJ's SMR Rating (36) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (77). This means that JNJ’s stock grew somewhat faster than PFE’s over the last 12 months.
JNJ's Price Growth Rating (11) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (57). This means that JNJ’s stock grew somewhat faster than PFE’s over the last 12 months.
JNJ's P/E Growth Rating (13) in the Pharmaceuticals Major industry is in the same range as PFE (43). This means that JNJ’s stock grew similarly to PFE’s over the last 12 months.
| JNJ | PFE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 31% | 2 days ago 63% |
| Stochastic ODDS (%) | 2 days ago 46% | 2 days ago 51% |
| Momentum ODDS (%) | 2 days ago 48% | 2 days ago 47% |
| MACD ODDS (%) | 2 days ago 33% | 2 days ago 47% |
| TrendWeek ODDS (%) | 2 days ago 44% | 2 days ago 59% |
| TrendMonth ODDS (%) | 2 days ago 48% | 2 days ago 55% |
| Advances ODDS (%) | 2 days ago 44% | 9 days ago 54% |
| Declines ODDS (%) | 10 days ago 42% | 5 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 42% | 2 days ago 57% |
| Aroon ODDS (%) | 2 days ago 42% | 2 days ago 59% |
Advertisement
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | +0.77% | ||
| BMY - PFE | 61% Loosely correlated | +1.23% | ||
| MRK - PFE | 55% Loosely correlated | +2.36% | ||
| AMGN - PFE | 53% Loosely correlated | +1.49% | ||
| NVS - PFE | 51% Loosely correlated | +2.00% | ||
| BIIB - PFE | 51% Loosely correlated | +1.46% | ||
More | ||||